open access

Vol 74, No 1 (2006)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22
Get Citation

Efficacy and safety of levofloksacin treatment of community - acquired pneumonia in hospitalized patients

Krzysztof J. Karwat, E. Grabczak, Ryszarda Chazan
Pneumonol Alergol Pol 2006;74(1):77-79.

open access

Vol 74, No 1 (2006)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22

Abstract

The aim of this prospective study was to determine the efficacy and safety of levofloxacin in the treatment of community-aquired pneumonia (CAP) in outpatient with ineffective antibiotic management, requiring hospitalization. The examined group included 25 patients (11 M, 14 F) of mean age 70 &plusmn; 17,5 years with abnormalities in X-ray on admission to hospital. Risk factors for pneumonia and previous antibacterial therapy were analyzed. In the hospital they were treated for 7 days with levofloxacin 500 mg twice a day administred intravenously. Body temperature, blood cell count, ESR, CRP, AST, ALT, LDH, CPK, creatine, urea, potassium, sodium, ABG, and ECG were measured on admission and in the 3-rd and 7-th day of therapy. The chest X-rays were performed and analyzed on hospital discharge. 18 patients were aged > 65 yrs, cardiovascular diseases co-existed in 14, COPD in 9, smoking habit in 12, renal failure in 3, diabetes in 3 and alkohol addiction in 1 cases. On admission 4 patients had respiratory failure, 10 hypoxaemia. During therapy a decrease of body temperature (p < 0,001), concentration of CRP (p < 0,004) and LDH (p < 0,03), CPK (p < 0,04) and increase of PaO2 (p < 0,012) were observed. The changes of other parameters were not statistically significant. We did not observe any changes in ECG. Ond ischarge from the hospital in 16 patients complete regression and in 6 patients partial regression of lesions in chest X-ray examination were observed. In 3 patients levofloxacin therapy was non effective: in 2 because of persistent high body temperature after 3 days of treatment and in 1 patients because of recurrent of fever. Adverse events were mild. Transient exacerbation of renal failure was observed in 3 patients. Our study demonstrates that levofloxacine ni dose 2x500 mg given intravenously for 7 days is effective and safe in treatment of CAP in patients with previously ineffective antibacterial therapy.

Abstract

The aim of this prospective study was to determine the efficacy and safety of levofloxacin in the treatment of community-aquired pneumonia (CAP) in outpatient with ineffective antibiotic management, requiring hospitalization. The examined group included 25 patients (11 M, 14 F) of mean age 70 &plusmn; 17,5 years with abnormalities in X-ray on admission to hospital. Risk factors for pneumonia and previous antibacterial therapy were analyzed. In the hospital they were treated for 7 days with levofloxacin 500 mg twice a day administred intravenously. Body temperature, blood cell count, ESR, CRP, AST, ALT, LDH, CPK, creatine, urea, potassium, sodium, ABG, and ECG were measured on admission and in the 3-rd and 7-th day of therapy. The chest X-rays were performed and analyzed on hospital discharge. 18 patients were aged > 65 yrs, cardiovascular diseases co-existed in 14, COPD in 9, smoking habit in 12, renal failure in 3, diabetes in 3 and alkohol addiction in 1 cases. On admission 4 patients had respiratory failure, 10 hypoxaemia. During therapy a decrease of body temperature (p < 0,001), concentration of CRP (p < 0,004) and LDH (p < 0,03), CPK (p < 0,04) and increase of PaO2 (p < 0,012) were observed. The changes of other parameters were not statistically significant. We did not observe any changes in ECG. Ond ischarge from the hospital in 16 patients complete regression and in 6 patients partial regression of lesions in chest X-ray examination were observed. In 3 patients levofloxacin therapy was non effective: in 2 because of persistent high body temperature after 3 days of treatment and in 1 patients because of recurrent of fever. Adverse events were mild. Transient exacerbation of renal failure was observed in 3 patients. Our study demonstrates that levofloxacine ni dose 2x500 mg given intravenously for 7 days is effective and safe in treatment of CAP in patients with previously ineffective antibacterial therapy.
Get Citation

Keywords

community-aquired pneumonia; levofloxacin; pneumoniatreatment

About this article
Title

Efficacy and safety of levofloksacin treatment of community - acquired pneumonia in hospitalized patients

Journal

Advances in Respiratory Medicine

Issue

Vol 74, No 1 (2006)

Pages

77-79

Published online

2008-02-18

Bibliographic record

Pneumonol Alergol Pol 2006;74(1):77-79.

Keywords

community-aquired pneumonia
levofloxacin
pneumoniatreatment

Authors

Krzysztof J. Karwat
E. Grabczak
Ryszarda Chazan

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl